TürkiyeResearch and clinical trials
11 children with XLA in Elazığ: diagnosed at a median age of 4.5 years, with fewer infections on treatment
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
Long-term records of children with X-linked agammaglobulinemia were reviewed at Fırat University in Elazığ. The study included 11 boys followed over a period of twenty years. Symptoms began at a median age of 12.7 months, while diagnosis was made at a median age of 4.5 years. Diagnosis was delayed more in children with no affected family members. With immune support therapy and preventive antibiotics, the yearly number of infections fell from 16.9 to 2.09.
What does it mean for patients and families?
If this disease runs in the family, testing baby boys early can speed up diagnosis. This is a small, single-center study; the treatment plan is made with an immunologist.
Source
Scientific paper: Beyond Recurrent Infections: Immune Dysregulation Manifestations, Genotype-phenotype Heterogeneity, and Three Novel BTK Variants in X-linked Agammaglobulinemia. Iranian Journal of Allergy, Asthma, and Immunology, 2026. DOI: 10.18502/ijaai.v25is11.22497 · PubMed 42825907
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: X-linked agammaglobulinemia (Bruton disease)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.